What patent protection does Intrarosa have, and for how long?
Intrarosa (prasterone vaginal inserts) is protected through a mix of patent rights and regulatory exclusivity tied to its approval. Exact coverage depends on the specific patent(s) listed for the product and the country where you’re asking, because patent terms and listing status differ by jurisdiction and by formulation/indication.
When does Intrarosa’s exclusivity/patent protection end?
The end date a patient, competitor, or investor would care about is typically the later of:
- the patent term for the most relevant listed patent(s), and
- the date(s) for regulatory exclusivity that can block certain generic or “less-than-innovator” pathways even if a patent expires.
Because “Intrarosa patent protection” could mean different mechanisms (a listed drug patent vs. exclusivity vs. a specific filing), you generally need the jurisdiction and the exact formulation/claim being tested to determine the practical launch window.
What counts as “patent protection” in practice for drug makers like Intrarosa?
For branded products, “patent protection” in day-to-day market terms usually refers to:
- listed patents that must be addressed before a competitor can market an alternative, and
- any exclusivity period that can prevent approval or marketing even if a patent challenge succeeds.
This is why generic entry timing often hinges on the combination of patent listings and exclusivity, not the generic expiration of a single patent.
Where to find the authoritative list of Intrarosa’s protecting patents
If you’re trying to determine specific dates, the most reliable approach is to pull the protecting-patent listings from the relevant national drug registry (for the US, this is typically done through the Orange Book listing for Intrarosa, which lists patents associated with the approved product and their expiration dates).
Those listings also help identify:
- which patents are method-of-use vs. composition vs. formulation,
- which patents have different expiration dates, and
- what a challenger would need to address.
Are there litigation or challenges that affect when generics could launch?
Patent challenges and litigation can change real-world timing. Even when a competitor files an abbreviated application, marketing may be delayed by:
- a court finding of patent infringement or non-infringement,
- settlement agreements that set “launch” or “carve-out” dates, and/or
- remaining unexpired patents covering the product.
Without the specific court docket or the jurisdiction, it’s not possible to state whether Intrarosa has an active case that changes the calendar.
What should you check to answer “can a generic come out yet?” for Intrarosa?
To figure out whether a competitor can launch, you need:
- the country (US vs. EU vs. other),
- whether you mean generic, biosimilar (not applicable here in the usual sense), or a different prasterone vaginal product,
- the exact product definition (strength/formulation),
- the patent(s) and their expiration dates from the local registry, and
- whether regulatory exclusivity is still in force for that indication.
If you tell me the country (and, if US, whether you want the Orange Book patents and expiration dates), I can translate that into the practical “earliest likely entry” window based on the protecting rights.
Quick clarification to narrow it down
Are you asking about Intrarosa patent protection in the US or another country? And do you want the exact protecting patent numbers/expiration dates (from a drug-patent registry), or just the general timeframe when competitors can enter?
Sources
No sources were provided in the prompt.